Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Speratum Biopharma Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, producing a concentrated prosecution profile.
ELKINS, BLAKE HARRISON is the busiest examiner, with 1 pending matter. Counsel can focus on the individual examination record and the requirements associated with that art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELKINS, BLAKE HARRISON | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556623 | SUBSTRATE SEQUENCE DESIGN WORKFLOW FOR THE RNAI-MEDIATED MULTI-SITE REGULATION OF GENOMIC AND SUB-GENOMIC VIRAL RNAS | ELKINS, BLAKE HARRISON | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556623 | SUBSTRATE SEQUENCE DESIGN WORKFLOW FOR THE RNAI-MEDIATED MULTI-SITE REGULATION OF GENOMIC AND SUB-GENOMIC VIRAL RNAS | ELKINS, BLAKE HARRISON | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSperatum Biopharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Blake Harrison Elkins has the most, with 1 of Speratum Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
